Acino (SIX: ACIN) is a Swiss-based pharmaceutical company which was founded in 1836 and which develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms.

Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in 80 fast-growing emerging economies in the Middle East, Africa, Latin America and Asia. In total, Acino operates in 130 countries, employing 790 FTEs and has exclusive access to a 400 person sales force in emerging markets.

On December 12, 2013, Pharma Strategy Partners GmbH, an indirect subsidiary of Nordic Capital Fund VII and its co-investor Avista Capital Partners, successfully completed its public tender offer for Acino Holding AG. The Acino shares have consequently been delisted from the stock exchange.

  • Kalle Känd, CEO
  • Geir Myklebust, CFO
Key Information: Revenues 2016*: EUR 270 million Employees: 1310 Ownership: Nordic Capital Fund VII Date of investment: 2013 Head office: Zurich, Switzerland
* Reported